Correlation Between Crispr Therapeutics and ATyr Pharma
Can any of the company-specific risk be diversified away by investing in both Crispr Therapeutics and ATyr Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Crispr Therapeutics and ATyr Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Crispr Therapeutics AG and ATyr Pharma, you can compare the effects of market volatilities on Crispr Therapeutics and ATyr Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Crispr Therapeutics with a short position of ATyr Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Crispr Therapeutics and ATyr Pharma.
Diversification Opportunities for Crispr Therapeutics and ATyr Pharma
0.05 | Correlation Coefficient |
Significant diversification
The 3 months correlation between Crispr and ATyr is 0.05. Overlapping area represents the amount of risk that can be diversified away by holding Crispr Therapeutics AG and ATyr Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ATyr Pharma and Crispr Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Crispr Therapeutics AG are associated (or correlated) with ATyr Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ATyr Pharma has no effect on the direction of Crispr Therapeutics i.e., Crispr Therapeutics and ATyr Pharma go up and down completely randomly.
Pair Corralation between Crispr Therapeutics and ATyr Pharma
Given the investment horizon of 90 days Crispr Therapeutics AG is expected to generate 0.33 times more return on investment than ATyr Pharma. However, Crispr Therapeutics AG is 3.02 times less risky than ATyr Pharma. It trades about -0.03 of its potential returns per unit of risk. ATyr Pharma is currently generating about -0.04 per unit of risk. If you would invest 6,865 in Crispr Therapeutics AG on August 27, 2024 and sell it today you would lose (2,077) from holding Crispr Therapeutics AG or give up 30.25% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Insignificant |
| Accuracy | 53.23% |
| Values | Daily Returns |
Crispr Therapeutics AG vs. ATyr Pharma
Performance |
| Timeline |
| Crispr Therapeutics |
| ATyr Pharma |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Crispr Therapeutics and ATyr Pharma Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Crispr Therapeutics and ATyr Pharma
The main advantage of trading using opposite Crispr Therapeutics and ATyr Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Crispr Therapeutics position performs unexpectedly, ATyr Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ATyr Pharma will offset losses from the drop in ATyr Pharma's long position.| Crispr Therapeutics vs. Eliem Therapeutics | Crispr Therapeutics vs. HCW Biologics | Crispr Therapeutics vs. Scpharmaceuticals | Crispr Therapeutics vs. Milestone Pharmaceuticals |
| ATyr Pharma vs. Mereo BioPharma Group | ATyr Pharma vs. Terns Pharmaceuticals | ATyr Pharma vs. PDS Biotechnology Corp | ATyr Pharma vs. Inozyme Pharma |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Complementary Tools
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |